Glenmark Pharmaceuticals is currently trading at Rs. 603.40, up by 2.40 points or 0.40% from its previous closing of Rs. 601.00 on the BSE.
The scrip opened at Rs. 600.00 and has touched a high and low of Rs. 609.35 and Rs. 600.00 respectively. So far 6645 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 612.00 on 12-Jul-2013 and a 52 week low of Rs. 361.00 on 26-Jul-2012.
Last one week high and low of the scrip stood at Rs. 612.00 and Rs. 582.05 respectively. The current market cap of the company is Rs. 16397.29 crore.
The promoters holding in the company stood at 48.30% while Institutions and Non-Institutions held 40.97% and 10.73% respectively.
A suit had been filed against Glenmark Generics, a subsidiary of Glenmark Pharmaceuticals in the United States District Court by UCB INC., UCS Pharma GmbH, Research Corporation Technologies Inc. and Harris FRC Corporation, seeking to prevent Glenmark from commercializing its ANDA product prior to the expiration of US Patent. If Glenmark is successful in its challenge of the patent, it will garner 180-day exclusivity for its products.
Glenmark Generics had filed Abbreviated New Drug Applications (ANDAs) for Lacosamide Tablets, and Oral Solution with the US Food and Drug Administration (USFDA) with a Paragraph IV Certification for the Orange-Book listed patent. Glenmark’s ANDA products are generic versions of VIPMAT.
According to IMS health data for the twelve months ending March 31, 2013, VIPMAT tablets and Solution had total US sales of approximately $353 million.
Company Name | CMP |
---|---|
Sun Pharma Inds. | 1819.00 |
Dr. Reddys Lab | 1378.85 |
Cipla | 1487.45 |
Lupin | 2232.60 |
Zydus Lifesciences | 1010.20 |
View more.. |